MultiOmic Health Secures $6.2 Million

MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, has closed a £5 million (US$6.2 million) seed funding extension round to build its precision therapeutics discovery platform for metabolic syndrome-related medical conditions.

MMC was proud to participate in the round, alongside Hoxton Ventures, Ada Ventures, and Verve Ventures.

Existing treatments for metabolic syndrome-related conditions merely reduce risk or delay onset of serious consequences such as heart attack, stroke, kidney failure, blindness, nerve damage, foot amputation, liver failure and premature death. Patients’ disease journeys exhibit immense heterogeneity, reflecting potentially hundreds of different disease variants that result not only from inherited genetics, but also diet, lifestyle and other environmental factors. Unlike cancer however, there are no existing precision medicines to tackle the specific molecular-level drivers of each metabolic syndrome disease variant.

We will address this huge unmet medical need by systematically discovering, at scale, unique treatment concepts for these different disease variants. Our human-centric platform originates therapeutics from high-fidelity patient data, reversing the traditional drug discovery models that initiate treatments from test tube and animal experiments. We are going from bedside to lab bench, rather than from lab bench to bedside!

ROBERT THONGCO-FOUNDER AND CEO, MULTIOMIC

The proceeds of the financing round will be used to demonstrate proof-of-concept for MultiOmic’s MOHSAIC^® platform, which combines :

Machine learning and other AI techniques to analyse complex multi-omics patient data and corresponding longitudinal clinical information;
Systems biology simulations of disease pathways; and
Iterative refinement and validation of in silico findings using targeted wet lab experiments.

Building a computational systems biology engine founded on a deep integrated omics dataset is the only way to address the knowledge gap in metabolic diseases. Robert has assembled a top-tier multi-disciplinary team to address this complex data problem

CHARLOTTE BARTTELOTPRINCIPAL, MMC VENTURES

For more on MultiOmic Health’s funding round, see media coverage by Silicon Canals and FinSMEs.